AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
142_CD
Form_NN
20-F_JJ
Information_NOMZ
2005_CD
NOTES_NN
TO_PIN
THE_DT
FINANCIAL_NN
STATEMENTS_NOMZ
1_CD
FIXED_NN
ASSET_NN
INVESTMENTS_NOMZ
Investments_NOMZ
in_PIN
subsidiaries_NN
Shares_NN
Loans_NN
Total_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Cost_NN
at_PIN
beginning_GER
of_PIN
year_NN
6,715_CD
24,197_CD
30,912_CD
Additions_NOMZ
Repayment_NOMZ
of_PIN
loan_NN
6,056_CD
6,056_CD
Net_JJ
book_NN
value_NN
at_PIN
31_CD
December_NN
2005_CD
6,715_CD
18,141_CD
24,856_CD
Net_JJ
book_NN
value_NN
at_PIN
31_CD
December_NN
2004_CD
6,715_CD
24,197_CD
30,912_CD
2_CD
OTHER_NN
DEBTORS_NN
2005_CD
2004_CD
$_$
m_CD
$_$
m_CD [BEMA]
Other_JJ
debtors_NN
10_CD
Deferred_JJ
tax_NN
asset_NN
17_CD
25_CD
27_CD
25_CD
3_CD
NON-TRADE_JJ
CREDITORS_NN
2004_CD
2005_CD
restated_VBN
$_$
m_CD
$_$
m_CD
Amounts_NN
due_JJ
within_PIN
one_CD
year_NN
Short_JJ
term_NN
borrowings_GER
unsecured_JJ
5_CD
4_CD
Other_JJ
creditors_NN
5_CD
116_CD
Amounts_NN
owed_VBN [WZPAST]
to_PIN
subsidiaries_NN
10_CD
2,409_CD
20_CD
2,529_CD
4LOANS_NN
Repayment_NOMZ
2005_CD
2004_CD
dates_NN
$_$
m_CD
$_$
m_CD [PASS]
Loans_NN
owed_VBD
to_PIN
subsidiaries_NN
unsecured_JJ
US_FPP1
dollars_NN
7.2_CD
%_NN
loan_NN
2023 283 283_CD
Loans_NN
external_JJ
unsecured_JJ
US_FPP1
dollars_NN
5.4_CD
%_NN
callable_JJ
bond_NN
2014 747 747_CD
1,030_CD
1,030_CD
Loans_NN
or_CC
instalments_NOMZ
thereof_RB
are_VPRT [BEMA]
repayable_PRED
:_:
After_IN
five_CD
years_NN
from_PIN
balance_NN
sheet_NN
date_NN
1,030_CD
1,030_CD
From_PIN
two_CD
to_PIN
five_CD
years_NN
From_PIN
one_CD
to_PIN
two_CD
years_NN
Total_JJ
unsecured_JJ
1,030_CD
1,030_CD
Total_JJ
due_JJ
within_PIN
one_CD
year_NN
1,030_CD
1,030_CD
The_DT
fair_JJ
values_NN
of_PIN
the_DT
external_JJ
loans_NN
and_CC
the_DT
loans_NN
owed_VBN [WZPAST]
to_PIN
subsidiaries_NN
are_VPRT
as_IN
follows_VPRT
:_:
2005_CD
2004_CD
$_$
m_CD
$_$
m_CD [BEMA]
7.2_CD
%_NN
loan_NN
341_CD
338_CD
5.4_CD
%_NN
callable_JJ
bond_NN
770_CD
789_CD
1,111_CD
1,127_CD
Both_DT
loans_NN
are_VPRT [BEMA]
at_PIN
fixed_JJ
interest_NN
rates_NN
._.
Accordingly_RB
the_DT
fair_JJ
values_NN
of_PIN
the_DT
loans_NN
will_PRMD
change_VB
as_IN
market_NN
rates_NN
change_VPRT
._.
However_CONJ
,_,
since_OSUB
the_DT
loans_NN
are_VPRT [PASS]
held_VBN [PRIV]
at_PIN
amortised_JJ
cost_NN
,_,
changes_NN
in_PIN
interest_NN
rates_NN
and_CC
the_DT
credit_NN
rating_NN
of_PIN
the_DT
Company_NN
will_PRMD
not_XX0
have_VB
an_DT
effect_NN
on_PIN
the_DT
Companys_NN
net_JJ
assets_NN
._.
